Sponsors

Commerce and COVID-19: a need for reconfiguration and transformation

The in vitro diagnostics industry has been at the forefront of the fight against SARS-CoV-2. Here, Mark Reed provides a commercial perspective and overview of the unprecedented times experienced over the past 12 months.

Looking back at 2020, I am quite sure that there isn’t a diagnostic manufacturing or distribution company in the UK, or even the world, that hasn’t been affected in some way by the SARS-CoV-2 pandemic, be that professionally or personally.

            As coronavirus continues to spread, and mutate, so testing methods have developed to detect the virus more effectively. Testing has always been integral to diagnosis, understanding its spread, and taking preventive measures to protect populations. The more rapid and reliable the test, the quicker there can be a diagnosis.

A brief timeline review

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

Pathology Visions 24

Hyatt Regency, Orlando, FL
3-5 November, 2025

UK NEQAS Cellular Pathology Technique - Annual Participant’s Meeting

America Square Conference Centre, London, EC3N 2LB.
4 - 5 November, 2024

Medica

Messe Dusseldorf
11-14 November, 2024

POCT-for-Scot: Bringing the future to you

SEC Arena, Glasgow
14 November, 2024

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024